On September 7, 2022, Bioxytran, Inc. (“Bioxytran” or the “Company”) registered, in India, a fully owned subsidiary, Pharmalectin India Private Limited, (the “Subsidiary”). The purpose of the Subsidiary is to be the sponsor of the Company’s clinical trials and commercialize the Company’s products, in India. The Subsidiary’s Certificate of Registration is filed as Exhibit 21.5 hereto.
In connection with the issuance of the above registration, the Company issued, on December 14, 2022, a press-release over GlobeNewswire, filed as Exhibit 99.1 hereto, under the title:
“**Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization**”
On **December 14, 2022, Bioxytran (the “Company”) released an updated Corporate Presentation explaining the current state of the Company’s pharmaceutical development. The presentation is attached hereto as Exhibit 99.2.**
Folks the CEO of BIXT, OTC-QB, is run by an experienced ex-Billion dollar drug company CEO!!!
BOSTON,MASSACHUSETTS, December 14, 2022 (GLOBENEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)(the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that it has established an Indian subsidiary (Pharmalectin India PrivateLimited). The purpose of the subsidiary is to launch commercial product sales of ProLectin-M should the company receive Central Drugs Standard ControlOrganization (CDSCO) approval.
The Indian manufacturing plant is an FDA approved facility capable of supporting the Indian market with a population of 1.4 billion people